As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.
7 Analysts have issued a Ensysce Biosciences Inc forecast:
7 Analysts have issued a Ensysce Biosciences Inc forecast:
Mar '25 |
+/-
%
|
||
Revenue | 6.22 6.22 |
255%
255%
|
|
Gross Profit | - - |
-
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -6.85 -6.85 |
31%
31%
|
Net Profit | -6.82 -6.82 |
41%
41%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on proprietary technology platforms to develop safer prescription drugs. The firm's Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms, are in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. The company is headquartered in La Jolla, CA.
Head office | United States |
CEO | D. Kirkpatrick |
Employees | 8 |
Founded | 2003 |
Website | ensysce.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.